Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Employer self-insured plans, covering 64% of workers, model tangible productivity savings, which spur benefit adoption even when PBM rebates remain opaque
The Chosun Daily
Results of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, which compared dapagliflozin (10 mg once daily) to placebo, found that dapagliflozin was associated with a 44% reduction in a composite of adverse kidney outcomes and a 29% reduction in death from cardiovascular causes or hospitalization for heart failure
(10 g/kg)
US$ 20.65
US$ 28.19
US$ 25.20
US$ 23.11
US$ 27.48
US$ 22.32
